Evidence map›Paper›PMID 40854875›Full record

ArticleBlood cancer journal2025

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Akhil Rajendra, Elliot Smith, Maria Agustina Perusini, Kenny Tang, Eshetu G Atenafu, Aniket Bankar, Steven Chan, Marta B Davidson, Vikas Gupta, Dawn Maze and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Akhil RajendraDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-7167-4710
Elliot SmithPrincess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Maria Agustina PerusiniDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Kenny TangStaff Specialist Haematologist, Blacktown and Mt Druitt Hospital, Conjoint Lecturer Western Sydney University, Penrith, Australia.
Eshetu G AtenafuBiostatistics department, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4613-3680
Aniket BankarDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Steven ChanDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4354-0731
Marta B DavidsonDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Vikas GuptaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Dawn MazeDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4598-9380
Mark D MindenDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Guillaume Richard-CarpentierDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Aaron D SchimmerDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-4023-3899
Andre C SchuhDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Karen YeeDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-2572-9952
Hassan SibaiDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada. Hassan.Sibai@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40854875
PMCPMC12378385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.